Quanthealth secures $15M to bring its AI informed clinical drug trials to the US
Many biotech, pharmaceutical, and life sciences companies have high hopes for the potential of AI to make drug development more efficient. In fact, according to Deloitte, 38% of these companies have already integrated A.I. into their processes. QuantHealth is a company looking to contribute to this effort by utilizing a model that can predict the risks and outcomes associated with clinical trials.
A startup based in Tel Aviv has developed an innovative AI-powered platform for drug discovery that promises to minimize potential risks, optimize clinical trials, and predict patient response to treatment. The company announced that it raised $20 million, including $15 million from Series A funding.
After working in life science and drug development for over 30 years, we realized that the industry’s decreasing success rates in clinical trials were becoming unsustainable,” said Orr Inbar, co-founder and CEO of QuantHealth, in an interview with TechCrunch. He also cited Deloitte’s research, noting that returns on investment have reached record lows.
QuantHealth’s platform claims to have one of the most extensive integrated datasets, covering over 350 million patients and more than 700,000 biomedical graphs and clinical trials. According to Inbar, this sets them apart from their competitors. The company states that its model can accurately predict clinical trial outcomes with a success rate of 86% on the binary endpoint metric. The company can predict the success of a clinical trial with 86% accuracy based on its primary endpoint.
According to Inbar, over 90% of clinical trials that follow traditional planning methods fail to market due to safety and effectiveness concerns. In some cases, certain drugs should not be tested, while in others, poorly designed trials cause delays, increased expenses, and higher failure rates.
According to a recent case study, a QuantHealth client improved their phase 2 trial in acute respiratory distress syndrome significantly. The team accomplished this by simulating thousands of variations in the protocol, leading to minor but impactful changes. As a result, the target population increased by 4.5 times, the study duration reduced by 11 months, and the number of participants needed decreased by 251 individuals. Additionally, the primary endpoint’s success rate improved by 16.5%.
QuantHealth was established in 2020 and has operated actively for two years. The organization collaborates with pharma, biotechs, and clinical research organizations, continuously supporting their programs and regulators in both the United States and Europe.
QuantHealth recently announced its plans to expand its operations in the United States, which includes the appointment of David Dornstreich as the Chief Commercial Officer and Arnon Horev as the Chief Strategy and Operations Officer. The company, which has 25 employees in Israel and the U.S., aims to grow its workforce to 40 by next year.
Bertelsmann Investment and Pitango HealthTech have co-led the Series A funding. Other existing backers, namely Shoni Top Ventures, Nina Capital, and Nova Capital, also participated in the latest round of funding. With the new capital, the startup plans to enhance its flagship trial design solution to support clinical development teams. Additionally, it aims to expand its platform for preclinical and drug discovery functions and grow its commercial team and operations.